Carl Schmid discusses how the district court decision that HHS must require insurers to count copay assistance towards patient out-of-pocket costs helps to make prescription drugs more affordable and accessible for patients.
Carl Schmid of the HIV+Hepatitis Policy Institute joins Hannah Lynch, Associate Director, U.S. Public Policy at UCB, to discuss how we can evolve the healthcare system to better serve people living with severe diseases and help them overcome access barriers.
Carl Schmid participates in the “Prescription for Better Access” podcast with Lauren Crawford Shaver and hosts Mark Hansan and Dr. Scott Howell to examine how PBM copay accumulator and maximizer policies harm patients by not counting copay assistance toward patient out-of-pocket costs and deductibles, and what can be done to keep prescription drugs accessible and affordable.
Carl Schmid discusses discrimination in prescription drug formularies, demonstrating how some PBMs and private insurers violate ACA provisions and hurt patients by placing life-saving prescription drugs on higher cost tiers.
At Informa Connect’s Copay, Reimbursement and Access Congress, Carl Schmid discusses the litigation filed by HIV+Hep, the DLC, and the DPAC in the U.S. District Court for DC challenging a federal rule that allows health insurers to avoid counting the value of drug manufacturer copay assistance toward patients’ out-of-pocket cost obligations in violation of the ACA definition of and regulations for cost-sharing.